Page 1 of 5 — Full ranking, strongest to weakest · As of November 6, 2026 market close · 28 stocks · 33-criteria screen
# Ticker Company Price Score Verdict 12-mo PT Upside P/E Wk %
1 MU Micron Technology $690.00 24 of 33 (73%) ACCUMULATE (cyclical) $1,145 +66% 9.3 -22.0%
2 TSM Taiwan Semiconductor (ADR) $375.44 23 of 33 (70%) ACCUMULATE $510 +36% 24.4 -7.6%
3 GOOGL Alphabet Inc. (Class A) $284.78 23 of 33 (70%) ACCUMULATE $430 +51% 14.9 +1.8%
4 GS The Goldman Sachs Group $865.82 24 of 33 (73%) HOLD / ACCUMULATE ON WEAKNESS $1,000 +15% 12.4 -3.2%
5 NVDA NVIDIA Corporation $186.64 22 of 33 (67%) ACCUMULATE $315 +69% 23.6 -8.8%
6 VST* Vistra Corp. $124.80 22 of 33 (67%) ACCUMULATE ON WEAKNESS $190 +52% 16.8 -9.8%
7 DELL Dell Technologies $328.53 22 of 33 (67%) HOLD / ACCUMULATE $575 +75% 19.1 -22.6%
8 AMAT Applied Materials $332.72 20 of 33 (61%) HOLD $495 +49% 29.1 -14.7%
9 AMZN Amazon.com $259.30 19 of 33 (58%) HOLD $315 +21% 21.0 +7.9%
10 BABA Alibaba Group Holding $109.45 19 of 33 (58%) ACCUMULATE ON WEAKNESS $150 +37% 25.7 +11.6%
11 AXP American Express $320.99 19 of 33 (58%) HOLD $350 +9% 18.1 +0.6%
12 FCX Freeport-McMoRan Inc. $59.42 19 of 33 (58%) HOLD $74 +25% 25.0 -4.9%
13 NFLX Netflix, Inc. $63.41 19 of 33 (58%) ACCUMULATE on WEAKNESS $115 +81% 18.3 +2.1%
14 AMD Advanced Micro Devices, Inc. $449.04 18 of 33 (55%) HOLD $535 +19% 97.4 -11.1%
15 UBER Uber Technologies $68.59 17 of 33 (52%) HOLD $100 +46% 40.6 +5.1%
16 LLY Eli Lilly and Company $1,354.00 17 of 33 (52%) HOLD $1,510 +12% 43.9 -4.5%
17 SOFI SoFi Technologies $16.21 17 of 33 (52%) HOLD $19 +17% 29.5 -3.3%
18 MRVL Marvell Technology $141.20 17 of 33 (52%) HOLD / SPECULATIVE $235 +66% 68.9 -28.1%
19 VRT Vertiv Holdings Co $182.86 16 of 33 (48%) HOLD $355 +94% 34.2 -21.4%
20 PLTR Palantir Technologies $160.38 16 of 33 (48%) HOLD $190 +18% 112.9 -12.9%
21 TMO Thermo Fisher Scientific Inc. $694.76 15 of 33 (45%) HOLD $714 +3% 36.6 -0.3%
22 GLW Corning Incorporated $106.13 15 of 33 (45%) HOLD $150 +41% 43.0 -13.9%
23 HOOD Robinhood Markets, Inc. $80.91 14 of 33 (42%) HOLD / SPECULATIVE $100 +24% 37.3 -4.8%
24 AAPL Apple Inc. $342.37 12 of 33 (36%) HOLD $330 -4% 38.2 -0.7%
25 CRWD CrowdStrike Holdings, Inc. $216.90 10 of 33 (30%) HOLD $210 -3% 3887.1 -13.4%
26 IREN IREN Limited $21.64 10 of 33 (30%) HOLD / SPECULATIVE $65 +200% n/m -9.7%
27 DKNG DraftKings Inc. $18.51 8 of 33 (24%) AVOID $30 +62% n/m -11.5%
28 SNOW Snowflake Inc. $275.88 6 of 33 (18%) AVOID $350 +27% n/m -9.9%

HOW TO READ THIS TABLE

Ranking = score on our 33-criterion screen (quality, financial condition, growth, earnings, valuation, momentum, ownership/liquidity) from each stock's Analysis & Valuation workbook, all 28 priced at the November 6, 2026 close (the usual one-week cadence from the Oct 30 anchor). Score measures how completely a stock passes the screen — the PROFILE matters as much as the number. The Nov 2-6 window opened with seven Tier-3 prints - AAPL and PLTR (Nov 2, AMC), AMD (Nov 3, AMC), UBER (Nov 4, BMO), IREN and DKNG (Nov 5, AMC) and VST (Nov 6, BMO) - and was dominated by a sharp AI-stock selloff on Nov 5: MU -17.5%, AMD -17.3% (then +11% on Nov 6), MRVL -16.4%, AMAT -13.6%, TSM -10.8%, HOOD -10.3%, NVDA -9.3% and GS -6.4%; the causes are unverified except MRVL (its Nov 2 all-stock ~$115B Lumentum acquisition). Weekly losers: MRVL -28.1%, DELL -22.6%, MU -22.0%, VRT -21.4%, AMAT -14.7%, GLW -13.9% and CRWD -13.4%; BABA +11.6%, AMZN +7.9% and UBER +5.1% rebounded. Prints: AAPL FQ4 EPS $2.10 beat (revenue +12%, Dec-qtr guide +7-10%) but C29 flipped to fail (12/33); PLTR revenue +96% and EPS $0.44 beat but the stock sold the news (-12.9%); AMD beat and guided Q4 to ~$17B (+66% YoY) and gains +2 to 18; UBER's GAAP EPS of $0.25 (a $476M investment mark; non-GAAP $0.88) re-based its grid and cost it five tests (-5 to 17, now HOLD); IREN's balance-sheet tests were re-derived to fail (-2 to 10, net debt $4.4B); DKNG posted a GAAP loss of $0.94 and fell 21% (-2 to 8); VST's GAAP EPS of $3.25 includes a $559M hedge gain (+1 to 22). Score movers: DELL +3, AMD +2, GOOGL +2 and GLW +2 up; UBER -5, IREN -2, DKNG -2 and MU -2 down. MU keeps the lead at 24/33; TSM and GOOGL follow at 23, and GS shows 24 reported but 21 excluding three bank-structure artifacts, so it ranks below them; SNOW is still the floor at 6. Price targets flagged for re-derivation: MU, AAPL, AMD, UBER, VST, GOOGL, DKNG, IREN, MRVL (estimates do not yet reflect the Lumentum deal), CRWD, HOOD, GLW, VRT, SOFI, DELL and BABA; CRWD now trades ~3% above its $210 PT. Upcoming earnings: AMAT (Nov 12, AMC), NVDA (Nov 17, AMC, confirmed), BABA (Nov 18, BMO, confirmed), DELL (Nov 24, AMC), MRVL and CRWD (Dec 1), SNOW (~Dec 2) and MU (~Dec 16). 12-mo PT = our own price target. Bold rows = top 10 by score; full detail for ALL 28 tickers follows on the pages below.

IMPORTANT DISCLAIMER: This document is provided for informational and educational purposes only. It does not constitute investment, legal, tax, or other professional advice, and nothing contained herein should be construed as a recommendation, an offer to sell, or a solicitation of an offer to buy any security or other financial instrument, in any jurisdiction. The information presented is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed, and certain figures are estimates that may prove incorrect. Past performance is not indicative of future results, and all investments involve risk, including the possible loss of principal. Readers must conduct their own independent research and due diligence and should consult a duly licensed financial, legal, or tax professional regarding their individual circumstances before making any investment decision. The author and ACapital Group LLC accept no liability for any loss arising from the use of this material.
Equity Research - Series Ranking Report
ACapital Group LLC · November 6, 2026
by Carlos Artiles

iiReport — STOCK RANKING & PRICE TARGETS

Page 2 of 5 — Ranking detail: tactical, swing and 12-month price targets (all 28 tickers) · As of November 6, 2026 market close
Tactical = this week, from support/resistance and momentum. Intermediate = swing-position objective. 12-month = our valuation-based target (My Price Analysis).
1. MU $690.00 · 24 of 33 (73%) · ACCUMULATE (cyclical)12-mo: $1,145 +66%
Tactical: Hold support near $650 (then $576.45); reclaim the SMA-200 $756.73Intermediate: $756.73, then $879; PT $1,145 (stale)

MU slips -2 to 24/33 (still #1) on a -22.0% week to $690.00 (RSI 31.3, oversold; -17.5% on Nov 5, -33.4% on the month, though still +141.8% YTD): the quarter and 52-week momentum tests (C51, C52) flipped to fail. The quality sweep (Financial 4/4, Mgmt 3/3, Growth 3/3, Earnings 2/2) is intact, and price now sits below the SMA-200 ($756.73) and well under the SMA-50 ($961.64). Flag: the $1,145 PT predates the Sep 30 FY2026 print and is STALE - the Section-6 math (E77 x E78) points to ~$1,711 and is flagged on B88; queued for judgment re-derivation. Hold $650, then $576.45; reclaim $756.73. Our 12-month $1,145 (+66%). Next earnings est. ~Dec 16 (AMC).

2. TSM $375.44 · 23 of 33 (70%) · ACCUMULATE12-mo: $510 +36%
Tactical: Hold support near $351.19 (then $337.95); reclaim the SMA-200 $401.48Intermediate: $401.48, then $416; PT $510

TSM slips -1 to 23/33 (#2) on a -7.6% week to $375.44 (RSI 36.3; -10.8% on Nov 5, cause unverified): the quarter-performance test (C52) flipped to fail, and price is now below the SMA-200 ($401.48) and SMA-50 ($431.64). The EPS grid remains on the consistent 32 NTD/USD basis (TTM EPS $15.37). Hold $351.19, then $337.95; reclaim $401.48, then $416.44. Our 12-month $510 (+36%). Next earnings est. ~Jan 15, 2027.

3. GOOGL $284.78 · 23 of 33 (70%) · ACCUMULATE12-mo: $430 +51%
Tactical: Hold support near $277.07 (then $270.70); reclaim $296.49, then $324.89Intermediate: $324.89, then the SMA-50 $332.93; PT $430 (stale)

GOOGL rises +2 to 23/33 (#3) on a +1.77% week to $284.78 (RSI 29.9, oversold; -18.2% on the month, -20.4% on the quarter): C51 and C53 flipped to pass, and C53 is razor-thin. The 14.9x trailing P/E is an artifact of Q2 non-operating gains. Flag: the $430 PT is STALE - Q3 EPS was $2.12 vs ~$2.94-3.00 consensus, capex guidance is $195-205B and TTM FCF is only $19.75B; 25-28x on $13.82 gives $345-387, and the analyst average is ~$400. Hold $277.07, then $270.70; reclaim $296.49. Our 12-month $430 (+51%, to be re-derived). Next earnings est. ~Feb 2027.

4. GS $865.82 · 24 of 33 (73%) · HOLD / ACCUMULATE ON WEAKNESS12-mo: $1,000 +15%
Tactical: Hold support near $864.75 (then $854.45); reclaim $893.97Intermediate: $932.51 (SMA-50), then $956.20 (SMA-200); PT $1,000

GS holds 24/33 reported (flat; 21/33 excluding three bank-structure artifacts - current ratio, quick ratio and a negative-cash-flow P/CF pass) on a -3.2% week to $865.82 (RSI 40.3; -6.4% on Nov 5, -16.3% on the quarter). C43 flipped to pass and C51 to fail. Quality is elite for a bank (Mgmt 3/3, Growth 3/3, Earnings 2/2) and P/E is low at ~12.9x trailing with P/B ~2.40x, but earnings are peak-cycle and D/E and interest coverage are structural fails. Ranked below TSM and GOOGL on the tie-break because three of its passes are structural artifacts. Hold $864.75, then $854.45; reclaim $893.97. Our 12-month $1,000 (+15.5%). Next earnings ~mid-Jan 2027 (unconfirmed).

5. NVDA $186.64 · 22 of 33 (67%) · ACCUMULATE12-mo: $315 +69%
Tactical: Hold support near $181.46 (then $171.88); reclaim the SMA-200 $204.67Intermediate: $204.67, then $211.55; PT $315

NVDA slips -1 to 22/33 on a -8.8% week to $186.64 (RSI 30.8, oversold; -9.3% on Nov 5, -19.0% on the month): the 52-week performance test (C53) flipped to fail, and price is now below the SMA-200 ($204.67) and SMA-50 ($219.81). The Financial 4/4 + Mgmt 3/3 + Growth 3/3 + Earnings 2/2 sweep is intact. Hold $181.46, then $171.88; reclaim $204.67. Our 12-month $315 (+69%). Next earnings Nov 17 (AMC, confirmed) - the next Tier-3 roll.

6. VST $124.80 · 22 of 33 (67%) · ACCUMULATE ON WEAKNESS12-mo: $190 +52%
Tactical: Hold support near $117.27 (then $110.89 low); reclaim $138.37Intermediate: $138.37, then the SMA-50 $143.90; PT $190

VST rises +1 to 22/33 on a -9.81% week to $124.80 (RSI 39.7; -13.8% on Nov 4, -6.2% on Nov 5, then +10.6% on Nov 6) after the Q3 print (Nov 6 BMO): GAAP EPS $3.25 vs $1.75 (+86%, including a $559M unrealized hedge gain), revenue $6.35B (+27.7%), 2026 adjusted EBITDA guide raised to $7.1-7.5B, 2027 initiated at $7.7-8.5B and a new $1.5B buyback. C29 and C43 flipped to pass; C47 flipped to fail. D/E ~373% (Financial 1/4) and momentum 0/3 remain the caveats. Flag: the $190 PT is built on FY27 EPS ~$10.98 but consensus is now $9.53 (needs ~19.9x); adjusted-EPS consensus is unverified. Hold $117.27, then $110.89; reclaim $138.37. Our 12-month $190 (+52%, under review). Next earnings ~Feb 2027.

7. DELL $328.53 · 22 of 33 (67%) · HOLD / ACCUMULATE12-mo: $575 +75%
Tactical: Hold support near $315 (then $295.19); reclaim the SMA-200 $337.46Intermediate: $337.46, then $372.36; PT $575

DELL rises +3 to 22/33 on a -22.6% week to $328.53 (RSI 28.7, oversold; -42.8% on the month, though still +161% YTD): C32, C38 and C39 flipped to pass as price fell to 19x trailing / 15.5x forward, and it now trades below the SMA-200 ($337.46) for the first time. Negative book equity keeps P/B, ROE and D/E n.m. Flag: the Section-6 step-2 multiple (~21.3x, ~$450) is older than the $575 PT. Hold $315, then $295.19; reclaim $337.46, then $372.36; the SMA-50 ($505.02) is far above. Our 12-month $575 (+75%). Next earnings Nov 24 (AMC, confirmed).

IMPORTANT DISCLAIMER: This document is provided for informational and educational purposes only. It does not constitute investment, legal, tax, or other professional advice, and nothing contained herein should be construed as a recommendation, an offer to sell, or a solicitation of an offer to buy any security or other financial instrument, in any jurisdiction. The information presented is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed, and certain figures are estimates that may prove incorrect. Past performance is not indicative of future results, and all investments involve risk, including the possible loss of principal. Readers must conduct their own independent research and due diligence and should consult a duly licensed financial, legal, or tax professional regarding their individual circumstances before making any investment decision. The author and ACapital Group LLC accept no liability for any loss arising from the use of this material.
Equity Research - Series Ranking Report
ACapital Group LLC · November 6, 2026
by Carlos Artiles

iiReport — STOCK RANKING & PRICE TARGETS

Page 3 of 5 — Ranking detail: tactical, swing and 12-month price targets (all 28 tickers) · As of November 6, 2026 market close
8. AMAT $332.72 · 20 of 33 (61%) · HOLD12-mo: $495 +49%
Tactical: Hold support near $316.95 (then $300); reclaim $348.71, then $369.40Intermediate: $369.40, then $390.09; PT $495

AMAT holds 20/33 (flat) on a -14.7% week to $332.72 (RSI 30.5, oversold; -13.6% on Nov 5, -34.7% on the month): C41 flipped to pass and C51 to fail. Quality stays flawless (Mgmt 3/3, Growth 3/3, Earnings 2/2), but price is ~25% below the SMA-200 ($445.35) and SMA-50 ($444.84). Hold $316.95, then $300; reclaim $348.71. Our 12-month $495 (+49%). Next earnings Nov 12 (AMC; guide $10.25B revenue, $4.02 non-GAAP EPS) - the catalyst for the PT.

9. AMZN $259.30 · 19 of 33 (58%) · HOLD12-mo: $315 +21%
Tactical: Hold support near $253.95 (SMA-50; then $243.94); reclaim $266.03Intermediate: $266.03, then $273.23; PT $315

AMZN slips -1 to 19/33 on a +7.88% week to $259.30 (RSI 54.2), a rebound back above the SMA-50 ($253.95) and SMA-200 ($243.94): C8 (beta, 1.50 borderline) and C48 (forward P/E 26.19x vs the 26 benchmark) flipped to fail, while C51 flipped to pass. D/E is set at 49.7% (a hair pass). Section 6 (31.8x on $9.90 = $314.82) ties to the PT. Hold $253.95, then $243.94; reclaim $266.03. Our 12-month $315 (+21.5%). Next earnings est. ~Feb 2027.

10. BABA $109.45 · 19 of 33 (58%) · ACCUMULATE ON WEAKNESS12-mo: $150 +37%
Tactical: Hold support near $108.29 (then $105.29); reclaim $111.37Intermediate: $116.31, then the SMA-200 $124.64; PT $150

BABA holds 19/33 (flat) on an +11.64% week to $109.45 (RSI 57.7) that lifted it back to the SMA-50 ($108.29); C51 flipped to pass and C32 to fail (P/E 25.7x vs the 24 benchmark). Deep-value contrarian profile, but ROIC trails WACC and price is still ~12% below the SMA-200 ($124.64). Flags: ADS EPS carries FX translation noise and Section-6 E77 ($7.94 x 18.2 = $144.5) is below the $150 PT, which was built on ~$8.26 FY28. Hold $108.29, then $105.29; reclaim $111.37. Our 12-month $150 (+37%). Next earnings Nov 18 (BMO, confirmed).

11. AXP $320.99 · 19 of 33 (58%) · HOLD12-mo: $350 +9%
Tactical: Hold support near $316.25 (then $311.40); reclaim $325.22Intermediate: $325.22, then $337.33; PT $350

AXP holds 19/33 (flat, no flips) on a +0.6% week to $320.99 (RSI 51.9). Premium card issuer + network - Management 3/3, Growth 3/3, Earnings 2/2 - with Financial 1/4 structural (current/quick ratio n.m., D/E 168%, interest coverage n/a). Q3 GAAP EPS $5.42 includes a one-time $1.11 GBTG gain (adjusted $4.68). Hold $316.25, then $311.40; reclaim $325.22. Our 12-month $350 (+9.0%). Next earnings est. late Jan 2027 (unconfirmed).

12. FCX $59.42 · 19 of 33 (58%) · HOLD12-mo: $74 +25%
Tactical: Hold support near $57.90 (then $56.75); reclaim the SMA-200 $65.24Intermediate: $65.24, then $69.84 (SMA-50); PT $74

FCX holds 19/33 (flat, no flips) on a -4.88% week to $59.42 (RSI 31.3; -16.5% on the month), now ~9% below the SMA-200 ($65.24) and 15% below the SMA-50 ($69.84). Cheap only on forward peak-price EPS; copper prices drive earnings and trailing PEG uses a normalized 14% denominator. Hold $57.90, then $56.75; reclaim $62.47, then $65.24. Our 12-month $74 (+24.5%). Next earnings est. ~Jan 21, 2027.

13. NFLX $63.41 · 19 of 33 (58%) · ACCUMULATE on WEAKNESS12-mo: $115 +81%
Tactical: Hold support near $62.08 (then $61.39, the 52-week low); reclaim $65.56Intermediate: $66.25, then $67.82; PT $115

NFLX rises +1 to 19/33 on a +2.14% week to $63.41 (RSI 39.7); a Nov 4 +4.7% bounce faded, and price is 10.7% below the SMA-50 ($71.03) and 21.8% below the SMA-200 ($81.04). Cheap on earnings (18.3x trailing, 16.7x forward) but not confirmed by the tape or balance-sheet screen. ACCUMULATE ON WEAKNESS stands. Hold $62.08, then $61.39; reclaim $65.56. Our 12-month $115 (+81%). Next earnings est. ~Jan 20, 2027.

14. AMD $449.04 · 18 of 33 (55%) · HOLD12-mo: $535 +19%
Tactical: Hold support near $429.56 (then the SMA-200 $415.98); reclaim $459.80Intermediate: $488.78, then $504.80; PT $535

AMD rises +2 to 18/33 on a -11.1% week to $449.04 (RSI 38.4; -17.3% on Nov 5, +11% on Nov 6) after the Q3 print (Nov 3 AMC): revenue $13.377B (+45%), Data Center $8.55B (+97%), non-GAAP EPS $2.09 vs ~$1.97, GAAP EPS $1.46 (a $1.1B warrant charge offset by a tax benefit), FCF only $554M, and a Q4 guide of ~$17B (+66% YoY) vs ~$16.2B. C34, C41 and C42 flipped to pass; quarter momentum flipped to fail. At 97x trailing / ~28x FY27 the valuation is still demanding. Flag: the $535 PT (33.95x pre-print FY27 EPS $15.76) is stale; FY27 EPS of $17-18 implies ~$577-611. Hold $429.56, then $415.98; reclaim $459.80. Our 12-month $535 (+19%). Next earnings est. ~Feb 3, 2027.

IMPORTANT DISCLAIMER: This document is provided for informational and educational purposes only. It does not constitute investment, legal, tax, or other professional advice, and nothing contained herein should be construed as a recommendation, an offer to sell, or a solicitation of an offer to buy any security or other financial instrument, in any jurisdiction. The information presented is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed, and certain figures are estimates that may prove incorrect. Past performance is not indicative of future results, and all investments involve risk, including the possible loss of principal. Readers must conduct their own independent research and due diligence and should consult a duly licensed financial, legal, or tax professional regarding their individual circumstances before making any investment decision. The author and ACapital Group LLC accept no liability for any loss arising from the use of this material.
Equity Research - Series Ranking Report
ACapital Group LLC · November 6, 2026
by Carlos Artiles

iiReport — STOCK RANKING & PRICE TARGETS

Page 4 of 5 — Ranking detail: tactical, swing and 12-month price targets (all 28 tickers) · As of November 6, 2026 market close
15. UBER $68.59 · 17 of 33 (52%) · HOLD12-mo: $100 +46%
Tactical: Hold support near $67.73 (then $66.60); reclaim the SMA-50 $70.15Intermediate: $70.15, then the SMA-200 $72.94; PT $100

UBER falls -5 to 17/33 (now HOLD) despite a +5.1% week to $68.59 (RSI 50.3) after the Q3 print (Nov 4 BMO): gross bookings $59.8B (+20%), adjusted EBITDA $2.96B (+31%), revenue $14.77B (+9.6%) and a Q4 bookings guide of $63.25-65.25B, but GAAP EPS was $0.25 (a $476M pretax equity-investment mark; non-GAAP $0.88). The grid was re-based to GAAP (TTM $1.69), so trailing multiples jumped to 40.6x and C28, C32, C33, C41 and C43 flipped to fail; C51 flipped to pass. Forward multiples remain strong (15.5x FY27). The $100 PT is 22.6x FY27 $4.42 (re-based from 26.9x, which would imply ~$119). Hold $67.73, then $66.60; reclaim $70.15. Our 12-month $100 (+46%). Next earnings est. ~Feb 4, 2027.

16. LLY $1,354.00 · 17 of 33 (52%) · HOLD12-mo: $1,510 +12%
Tactical: Hold support near $1,333 (then $1,288); reclaim $1,418Intermediate: $1,453, then $1,500; PT $1,510

LLY slips -1 to 17/33 (HOLD) on a -4.48% week to $1,354.00 (RSI 61.1, down from 78 as the post-print spike faded; +15.8% on the month, +26% YTD): momentum dropped to 2/3 (C51 fail), but the trend is intact above the SMA-50 ($1,214) and SMA-200 ($1,100). Valuation is still full (46x trailing GAAP, ~30x FY27), Financial 1/4, and GAAP EPS is depressed by acquired IPR&D. Section 6 (32x on $47.22 = $1,511) ties to the PT. Hold $1,333.22, then $1,288.30; reclaim $1,418. Our 12-month $1,510 (+11.5%). Next earnings ~Feb 4, 2027 (unconfirmed).

17. SOFI $16.21 · 17 of 33 (52%) · HOLD12-mo: $19 +17%
Tactical: Hold support near $15.43 (then $14.22); reclaim $16.35Intermediate: $16.56, then $17.38; PT $19

SOFI holds 17/33 (flat) on a -3.28% week to $16.21 (RSI 50.8; -7.7% on Nov 5), giving back its post-print pop: C43 flipped to pass (PEG) and C51 to fail. Beta 2.24, short interest 16.9%, analyst target $20.84. Flag: the $19 PT (21.1x multiple) may need re-derivation against the FY27 guide of ~$0.90. Hold $15.43, then $14.22; reclaim $16.35, then $16.56. Our 12-month $19 (+17%). Next earnings est. ~late Jan 2027.

18. MRVL $141.20 · 17 of 33 (52%) · HOLD / SPECULATIVE12-mo: $235 +66%
Tactical: Hold support near $132.54 (then $128.49); reclaim $146.32Intermediate: $159.80, then $171.41; PT $235

MRVL holds 17/33 (flat) on a -28.1% week to $141.20 (RSI 26.2, deeply oversold; -16.4% on Nov 5, -48.6% on the month, 44% below the Oct 28 high), after its Nov 2 all-stock ~$115B Lumentum acquisition (4.5 MRVL shares per LITE share; MRVL holders ~67%; close 1H28): C42 flipped to pass and C52 to fail. Price sits ~25% below the SMA-200 ($185.05). Flag: the $235 PT and the estimates do NOT reflect the deal and need re-derivation once consensus includes it. Hold $132.54, then $128.49; reclaim $146.32. Our 12-month $235 (+66%). Next earnings Dec 1 (AMC, confirmed).

19. VRT $182.86 · 16 of 33 (48%) · HOLD12-mo: $355 +94%
Tactical: Hold support near $170.80 (then $162.01); reclaim $192.14Intermediate: $205.55, then $224.24; PT $355

VRT slips -1 to 16/33 on a -21.4% week to $182.86 (RSI 36.7; -25.0% on the month): the post-print rally fully unwound, leaving price 33% under the SMA-200 ($271.22). C47 flipped to pass; C51 and C53 flipped to fail. At 18.8x forward on the post-print FY27 consensus of $9.74, valuation looks better, but the $355 PT (36.4x; the old 39.5x implies ~$385) is flagged for re-derivation. Hold $170.80, then $162.01; reclaim $192.14. Our 12-month $355 (+94%). Next earnings ~Feb 2027 (unconfirmed).

20. PLTR $160.38 · 16 of 33 (48%) · HOLD12-mo: $190 +18%
Tactical: Hold support near $154.99 (then the SMA-200 $153.53); reclaim $171.70Intermediate: $178.34, then the SMA-50 $185.88; PT $190

PLTR rises +1 to 16/33 on a -12.89% week to $160.38 (RSI 31.2, oversold) after the Q3 print (Nov 2 AMC): revenue $2.313B (+96% YoY, +20% QoQ) vs ~$2.17B, GAAP and adjusted EPS $0.44 vs ~$0.41, US commercial $984M (+148%), adjusted operating margin 62%, and the FY26 revenue guide raised to $8.53B. It was a sell-the-news reaction: C36 and C46 flipped to pass while C52 flipped to fail (momentum 0/3). At 113x trailing / 94x forward the valuation is still extreme; the 200-day (~$153.5) is the level to watch. The $190 PT is 112x FY26 EPS $1.70 (+18.5%). Hold $154.99, then $153.53; reclaim $171.70. Next earnings ~Feb 2, 2027 (AMC, est.).

21. TMO $694.76 · 15 of 33 (45%) · HOLD12-mo: $714 +3%
Tactical: Hold support near $687.16 (then $676.94); reclaim $697.78Intermediate: $709.18, then $712.17 (52-week high); PT $714

TMO slips -1 to 15/33 (HOLD) on a -0.32% week to $694.76 (RSI 54.8), after setting a new 52-week high of $712.17 on Nov 4. Quality defensive compounder at a full price: Mgmt 3/3 + Growth 3/3 (adjusted basis only), Valuation 2/15 (36.7x GAAP / ~28x adjusted) and Financial 2/4. Q3 (Oct 21) adjusted EPS $6.68 beat $6.40 and guidance was raised. Add on pullbacks toward the SMA-50 (~$661). Hold $687.16, then $676.94; reclaim $697.78. Our 12-month $714 (+2.8%). Next earnings ~late Jan 2027.

IMPORTANT DISCLAIMER: This document is provided for informational and educational purposes only. It does not constitute investment, legal, tax, or other professional advice, and nothing contained herein should be construed as a recommendation, an offer to sell, or a solicitation of an offer to buy any security or other financial instrument, in any jurisdiction. The information presented is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed, and certain figures are estimates that may prove incorrect. Past performance is not indicative of future results, and all investments involve risk, including the possible loss of principal. Readers must conduct their own independent research and due diligence and should consult a duly licensed financial, legal, or tax professional regarding their individual circumstances before making any investment decision. The author and ACapital Group LLC accept no liability for any loss arising from the use of this material.
Equity Research - Series Ranking Report
ACapital Group LLC · November 6, 2026
by Carlos Artiles

iiReport — STOCK RANKING & PRICE TARGETS

Page 5 of 5 — Ranking detail: tactical, swing and 12-month price targets (all 28 tickers) · As of November 6, 2026 market close
22. GLW $106.13 · 15 of 33 (45%) · HOLD12-mo: $150 +41%
Tactical: Hold support near $101.83 (then $94.95); reclaim $110.50Intermediate: $118.77, then $128.49; PT $150

GLW rises +2 to 15/33 on a -13.93% week to $106.13 (RSI 29.8, oversold; -30.6% on the month) even as FY27 consensus rose to $4.53 (was $4.31): the two forward-valuation tests (C47, C48) flipped to pass at 33.1x. Price is ~32% below the SMA-200 ($156.20). The dividend of $0.28/quarter has been frozen since Feb 2023 (ex-date Nov 13). Flag: the stat page shows 1.72 / 0.92 / 64% (current / quick / D/E) vs the workbook's 1.81 / 0.98 / 71%, which was not cut. Hold $101.83, then $94.95; reclaim $110.50. Our 12-month $150 (+41%). Next earnings ~late Jan 2027.

23. HOOD $80.91 · 14 of 33 (42%) · HOLD / SPECULATIVE12-mo: $100 +24%
Tactical: Hold support near $75.51 (then $71.20); reclaim $87.41Intermediate: $91.99 (SMA-200), then $105.97 (SMA-50); PT $100

HOOD holds 14/33 (flat) on a -4.8% week to $80.91 (RSI 32.0; -10.3% on Nov 5, -24.4% on the month), ~12% under the SMA-200 ($91.99): C46 flipped to fail and C48 to pass. Post-print consensus is FY26 $2.48 / FY27 $3.41 (was $2.31 / $3.09), so the stock trades 29.3x FY27; the old 32.4x multiple would imply ~$110 against the $100 PT. Hold $75.51, then $71.20; reclaim $87.41. Our 12-month $100 (+24%). Next earnings ~Feb 2027 (unconfirmed).

24. AAPL $342.37 · 12 of 33 (36%) · HOLD12-mo: $330 -4%
Tactical: Hold support near $336.01 (then $298.81); reclaim $343.38Intermediate: $355.38, then $361.83; PT $330

AAPL slips -1 to 12/33 on a -0.7% week to $342.37 (RSI 51.5) after the FQ4 print (Nov 2 AMC): GAAP EPS $2.10 vs ~$1.99 (+14% YoY, including ~$0.05 tariff refund), revenue $114.48B (+12%), FY26 EPS $8.98, and a December-quarter guide of +7-10% revenue with 45-46% gross margin (memory costs). C29 flipped to fail (EPS growth +13.5% vs the 19% hurdle). Elite quality at a full valuation; price is ~4% above our $330 PT and above the analyst average, so there is no margin of safety. The PT is 34x FY27 $9.40 = ~$320 (flagged). Hold $336.01, then $298.81; reclaim $355.38. Our 12-month $330 (-3.6%). Next earnings ~Jan 29, 2027 (unconfirmed).

25. CRWD $216.90 · 10 of 33 (30%) · HOLD12-mo: $210 -3%
Tactical: Hold support near $213.22 (then $206.74); reclaim $230.69Intermediate: $241, then $250.43; PT $210

CRWD slips -1 to 10/33 HOLD on a -13.39% week to $216.90 (RSI 35.3; -9.9% on Nov 5), ~11% below the SMA-50 ($243.78). A first-rate franchise on a GAAP break-even income statement (P/E n.m.): Valuation 0/15. Price is now ~3% ABOVE our $210 PT and ~12% below the Street's $247. Hold $213.22, then $206.74; reclaim $230.69, then $241. Our 12-month $210 (-3.2%). Next earnings Dec 1 (AMC, est.).

26. IREN $21.64 · 10 of 33 (30%) · HOLD / SPECULATIVE12-mo: $65 +200%
Tactical: Hold support near $17.16 (then $15); reclaim $22.46Intermediate: $24.67, then $26.50; PT $65

IREN falls -2 to 10/33 (HOLD, speculative) on a -9.65% week to $21.64 (RSI 36.3; -44% on the quarter) after the Q1 FY27 print (Nov 5 AMC): revenue $228M (+66% QoQ, -5% YoY), AI Cloud $200M (+182% QoQ), GAAP EPS -$0.66, net loss $263M, adjusted EBITDA $66M, backlog $20.3B (+22% QoQ); the >$4B ARR target slipped to Jan-Feb 2027 and net debt rose to $4.43B. The stock fell 17% into the print and rebounded 20% after. Balance-sheet tests C12, C13 and C19 were re-derived to fail (current 1.60, quick 0.94, D/E 199.5%, ROE -23.4%); C38 flipped to pass (P/CF 3.5x on prepayments). The $65 PT is asset/contract-based (+200%) and should be revisited on ARR and financing. Hold $17.16, then $15; reclaim $22.46. Next earnings ~Feb 2027 (unconfirmed).

27. DKNG $18.51 · 8 of 33 (24%) · AVOID12-mo: $30 +62%
Tactical: Hold support near $16.55 (new 52-week low; then $16); reclaim $18.79Intermediate: $20.60, then $21.51; PT $30

DKNG falls -2 to 8/33 AVOID on a -11.48% week to $18.51 (RSI 37.8) after the Q3 print (Nov 5 AMC): GAAP EPS -$0.94 (net loss $469M) on revenue $1,329M (+16%), cost of revenue $900M vs ~$372M (gross margin 32%), FCF -$43.7M, equity $180M vs debt $2.28B (D/E ~1,270%). The stock fell 21.3% to a new 52-week low of $16.55; C19 and C38 flipped to fail. The 8-K was not retrievable (figures via S&P through stockanalysis), and consensus and guidance are unverified; C28 is a hardcoded pass that is unverified (7/33 if it flips). The $30 PT (+62%) rests on pre-print FY26 EPS $0.90 and needs a re-check. Hold $16.55, then $16; reclaim $18.79. Next earnings ~Feb 2027 (unconfirmed).

28. SNOW $275.88 · 6 of 33 (18%) · AVOID12-mo: $350 +27%
Tactical: Hold support near $266.36 (then $260.34); reclaim $295.04Intermediate: $306.08, then the SMA-50 $328.12; PT $350

SNOW holds 6/33 AVOID, the series floor, on a -9.87% week to $275.88 (RSI 33.6; -19.7% on the month), below its 20- and 50-day averages but above the SMA-200 ($241.04). No earnings in the window; no flips. Valuation 0/15 on negative GAAP EPS (IF-guards hold); growth and FCF are real but leave no margin of safety. Our $350 PT (+27%) rests on non-GAAP. Hold $266.36, then $260.34; reclaim $295.04. Next earnings ~Dec 2 (AMC, est.).

Sources: each ticker's recalculated Analysis & Valuation workbook (prices confirmed at the November 6, 2026 close via stockanalysis.com; EPS from SEC filings; estimates from S&P Global consensus). Tactical/intermediate levels derive from each workbook's support/resistance and moving averages. Regenerated November 6, 2026 — iiReport screening framework.
IMPORTANT DISCLAIMER: This document is provided for informational and educational purposes only. It does not constitute investment, legal, tax, or other professional advice, and nothing contained herein should be construed as a recommendation, an offer to sell, or a solicitation of an offer to buy any security or other financial instrument, in any jurisdiction. The information presented is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed, and certain figures are estimates that may prove incorrect. Past performance is not indicative of future results, and all investments involve risk, including the possible loss of principal. Readers must conduct their own independent research and due diligence and should consult a duly licensed financial, legal, or tax professional regarding their individual circumstances before making any investment decision. The author and ACapital Group LLC accept no liability for any loss arising from the use of this material.